BayBio Therapeutic Breakfast: Regulatory Environment for Pain Therapeutics


Life Sciences

Mountain View, CA

Stephen B. Thau

Stephen B. Thau

Speaking Engagement

Pain treatment is big business, with several multi-billion dollar per year pain therapeutics on the market, and several others with sales of more than $100 million per year. Misuse and abuse of pain drugs is also a big problem. According to the FDA, the misuse and abuse of pain therapies has increased significantly in the past five years. Looking to reverse this trend, the FDA is requiring manufacturers of opioid products to implement Risk Evaluation and Mitigation (REMS) strategies, which the agency is in the process of developing. On May 28, our panel of experts will discuss how the new REMS guidelines will change the landscape of pain therapies.

Stephen Thau
Co-chair, Life Sciences Practice, Morrison & Foerster LLP

Michael Leong, MD
Pain Medicine Specialist, Adjunct Assistant Professor, Stanford University Pain Management Center

Gayle Mills
Executive Vice President, Business Operations, ROXRO Pharma, Inc.

Pamela Palmer
Chief Medical Officer, AcelRx Pharmaceuticals, Inc.

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2019 Morrison & Foerster LLP. All rights reserved.